2025年12月23日,来自湖北武汉的翰思艾泰生物科技(武汉)股份有限公司Hanx Biopharmaceuticals (Wuhan) Co., Ltd.(以下简称“翰思艾泰”)在港交所正式上市。大跌30%。本次发行18,321,000股,最终发行价为32.00港元/股,发行规模约为5.9亿港元(约合7,500万美元)。候选新药中的核心产品HX009(一种自主研发的PD-1/SIRPα双功能抗体...
Source Link2025年12月23日,来自湖北武汉的翰思艾泰生物科技(武汉)股份有限公司Hanx Biopharmaceuticals (Wuhan) Co., Ltd.(以下简称“翰思艾泰”)在港交所正式上市。大跌30%。本次发行18,321,000股,最终发行价为32.00港元/股,发行规模约为5.9亿港元(约合7,500万美元)。候选新药中的核心产品HX009(一种自主研发的PD-1/SIRPα双功能抗体...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.